Monika Dezortova

Dr. Monika Dezortova

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Radiology
Verified
Journal Article
Closed access
PDPetr Dusek
Petr Dusek
ALArtem Lescinskij
Artem Lescinskij
FRFilip Ruzicka
Filip Ruzicka
JAJulio Acosta-Cabronero
Julio Acosta-Cabronero
RBRadan Bruha
Radan Bruha
MDMonika Dezortova
Monika Dezortova
Individuals with Wilson disease had widespread cerebral atrophy and diffuse iron accumulation in the deep gray matter nuclei at MRI whereby reduced putaminal volume was most associated with neurolo... Background Abnormal findings at brain MRI in patients with neurologic Wilson disease (WD) are characterized by signal intensity changes and cerebral atrophy. T2 signal hypointensities and atrophy a...

13 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TDTereza Dusilová
Tereza Dusilová
JKJan Kovář
Jan Kovář
ILIvana Laňková
Ivana Laňková
LTLenka Thieme
Lenka Thieme
MHMonika Hubáčková
Monika Hubáčková
MHMartin Haluzík
Martin Haluzík
Background: Metabolic-dysfunction-associated steatotic liver disease (MASLD) represents a major clinical complication of obesity. Methods: In this study, we used magnetic resonance (MR) methods to determine the effect of obesity treatment with semaglutide, a GLP-1 receptor agonist, on the liver fat content and selected metabolic variables. We investigated whether treatment would affect the acute response of liver fat to glucose and fructose administration and whether it would affect the fatty acid profile of VLDL-triglycerides. Sixteen obese non-diabetic men underwent a 16-week dietary intervention and 16-week treatment with subcutaneous semaglutide in a crossover design without a washout period. The order of the interventions was randomized. Results: After treatment, body weight of the subjects decreased by 5% and liver fat by a third, whereas dietary intervention had no impact on these parameters. The decrease in liver fat with semaglutide did not correlate with changes in body weight and other measures of adiposity and was unrelated to improved insulin sensitivity. Conclusions: The proportion of palmitic and palmitoleic acids in VLDL-triglycerides decreased after treatment, suggesting that the beneficial effects of semaglutide on liver fat are mediated by the suppression of de novo lipogenesis.

14 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
PSPetr Sedivy
Petr Sedivy
TDTereza Dusilova
Tereza Dusilova
MHMilan Hajek
Milan Hajek
MBMartin Burian
Martin Burian
Martin KrssakMartin Krssak
Martin Krssak
MDMonika Dezortova
Monika Dezortova
Most in vivo 31P MR studies are realized on 3T MR systems that provide sufficient signal intensity for prominent phosphorus metabolites. The identification of these metabolites in the in vivo spectra is performed by comparing their chemical shifts with the chemical shifts measured in vitro on high-field NMR spectrometers. To approach in vivo conditions at 3T, a set of phantoms with defined metabolite solutions were measured in a 3T whole-body MR system at 7.0 and 7.5 pH, at 37 °C. A free induction decay (FID) sequence with and without 1H decoupling was used. Chemical shifts were obtained of phosphoenolpyruvate (PEP), phosphatidylcholine (PtdC), phosphocholine (PC), phosphoethanolamine (PE), glycerophosphocholine (GPC), glycerophosphoetanolamine (GPE), uridine diphosphoglucose (UDPG), glucose-6-phosphate (G6P), glucose-1-phosphate (G1P), 2,3-diphosphoglycerate (2,3-DPG), nicotinamide adenine dinucleotide (NADH and NAD+), phosphocreatine (PCr), adenosine triphosphate (ATP), adenosine diphosphate (ADP), and inorganic phosphate (Pi). The measured chemical shifts were used to construct a basis set of 31P MR spectra for the evaluation of 31P in vivo spectra of muscle and the liver using LCModel software (linear combination model). Prior knowledge was successfully employed in the analysis of previously acquired in vivo data.

1 September 2001 in Acta Radiologica
Verified
Journal Article
Closed access
PDF file
MDMonika Dezortova
Monika Dezortova
MHM. Hajek
M. Hajek
JTJ. Tintera
J. Tintera
LHL. Hejcmanova
L. Hejcmanova
ESEva Syková
Eva Syková

17 January 2003 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
FSFilip Spaniel
Filip Spaniel
THT. Hájek
T. Hájek
JTJ. Tintěra
J. Tintěra
PHP. Harantová
P. Harantová
MDMonika Dezortova
Monika Dezortova
MHM. Hájek
M. Hájek

15 September 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
MBMartin Burian
Martin Burian
MHMilan Hajek
Milan Hajek
PSPetr Sedivy
Petr Sedivy
IMIrena Mikova
Irena Mikova
PTPavel Trunecka
Pavel Trunecka
MDMonika Dezortova
Monika Dezortova
Increased hepatic fat content (HFC) is a hallmark of non-alcoholic fatty liver (NAFL) disease, a common condition in liver transplant recipients. Proton MR spectroscopy (1H MRS) and MR imaging-based proton density fat fraction as the only diagnosis modality enable precise non-invasive measurement of HFC and, also, fatty acid profiles in vivo. Using 1H MRS at 3T, we examined 47 liver transplantation candidates and 101 liver graft recipients. A point-resolved spectroscopy sequence was used to calculate the steatosis grade along with the saturated, unsaturated and polyunsaturated fractions of fatty acids in the liver. The steatosis grade measured by MRS was compared with the histological steatosis grade. HFC, represented by fat fraction values, is adept at distinguishing non-alcoholic steatohepatitis (NASH), NAFL and non-steatotic liver transplant patients. Relative hepatic lipid saturation increases while unsaturation decreases in response to increased HFC. Additionally, relative hepatic lipid saturation increases while unsaturation and polyunsaturation both decrease in liver recipients with histologically proven post-transplant NASH or NAFL compared to non-steatotic patients. HFC, measured by in vivo 1H MRS, correlated well with histological results. 1H MRS is a simple and fast method for in vivo analysis of HFC and its composition. It provides non-invasive support for NAFL and NASH diagnoses.